Evaluation of Adiposity-Related Biomarkers as Metabolic Syndrome Indicators

Yun-Jung Bae¹, Se-Hong Kim², Ju-Hye Chung², Sang-Wook Song², Kyung-Soo Kim³, Mi-Kyung Kim⁴⁵, Oran Kwon⁴, Myung-Sook Choi⁵⁶, Mi-Kyung Sung⁶⁷*

¹Department of Food and Nutritional Sciences, Hanbuk University, Dongduchen 483-120, Korea
²Department of Family Medicine, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea
³Department of Family Medicine & Integrative Medicine, Seoul St. Mary's Hosp., Catholic University Medical Center, Seoul 137-040, Korea
⁴Department of Nutritional Science and Food Management, Ewha Woman's University, Seoul 120-750, Korea
⁵Department of Food Science and Nutrition, Daegu 702-701, Korea
⁶Center for Food & Nutritional Genomics, Kyungpook National University, Daegu 702-701, Korea
⁷Department of Food and Nutrition, Sookmyung Women's University, Seoul 140-742, Korea

Recent studies have suggested a relationship of the increased circulating adipokines and inflammatory cytokine, and the risk of metabolic syndrome (MetS). The objective of this study was to identify adiposity-related factors that reflect MetS in order to establish early intervention targets. We performed a cross-sectional study which included 108 MetS subjects and 91 controls. Blood adiponectin, leptin, vascular-, and intercellular adhesion molecules (VCAM, ICAM), monocyte chemoattractant protein 1 (MCP1), high-sensitivity C-reactive protein (hsCRP), oxidized LDL (oxLDL), tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were measured. The correlation analysis indicated that the MetS score (sum of the number of MetS risk factors) had an inverse relationship with adiponectin (p < 0.0001), and positive correlations with leptin (p < 0.05), ICAM (p < 0.01), MCP1 (p < 0.05), oxLDL (p < 0.05), TNF-α (p < 0.0001), IL-6 (p < 0.05) and hsCRP (p < 0.01). In multivariate logistic regression analyses, plasma triglyceride (TG) was independently associated with adiponectin, ICAM and TNF-α with the standardized β coefficients of -0.213, 0.197, and 0.193, respectively. Plasma HDL-cholesterol was independently associated with ICAM and hsCRP with the standardized β coefficients of -0.150 and -0.173. Adiponectin, TNF-α, and hsCRP were the most proximate markers reflecting MetS. Among MetS components, TG and HDL-cholesterol concentrations displayed the relationship with inflammatory markers measured in this study.

Key Words: Metabolic syndrome, Adiposity, Adipokines, Inflammatory cytokines, Abdominal fat

Introduction

Metabolic syndrome (MetS) describes the clustering of abdominal obesity, lipid abnormalities, hypertension, and hyperglycemia. It is a strong independent contributor to the onset of type 2 diabetes and cardiovascular disease (CVD). The prevalence of MetS is 20-30% among adult populations in most countries [1], and it appears to correlate with the sharp increase in the incidence of metabolic diseases. Therefore, the identification of subjects with MetS and the importance of early effective intervention based on appropriate biomarkers have been emphasized.
Current evidence has shown that obesity plays a central role in the development of MetS, and significantly contributes to the further development of metabolic diseases [2]. The pathogenesis model disclosed that MetS is associated with metabolic stresses as a consequence of adipose cell enlargement and the associated changes in circulating inflammatory cytokine and adipokines [3]. Obesity-related chronic or low-grade systemic inflammation is considered to be a common in both insulin resistance and atherogenesis [4] which promotes the development of type 2 diabetes and atherosclerosis [5].

Adipokines are cytokines mainly produced by the adipose tissue. Leptin, adiponectin, resistin and visfatin are known to contribute to inflammatory responses [6]. Adiponectin inhibits the nuclear factor-κB (NF-κB)-dependent synthesis of tumour-necrosis factor (TNF) and interferon-γ (IFNγ), and induces the production of interleukin-10 (IL-10) and IL-1 receptor antagonist (IL-1RA) [7]. Leptin signals to induce activation of the mitogen-activated protein kinases (MAPKs) p38 and extracellular-signal-regulated kinase (ERK), and induces the production of nitric oxide synthase 2 (NOS2) and reactive oxygen species (ROS) [8]. Adiponectin induces apoptosis of monocytes and inhibits phagocytosis by macrophages, whereas leptin enhances macrophage phagocytosis and induces the activation, proliferation and migration of monocytes [6,7].

Biomarkers of systemic inflammation other than adipokines include pro-inflammatory cytokines and chemokines which have been suggested to be closely related to excess adipose tissue accumulation [9]. TNF-α, which can initiate both acute and chronic inflammation increases production of IL-6 and monocyte chemoattractant protein 1 (MCP1), and facilitates endothelial dysfunction [10]. MCP1, a mediator for T lymphocyte recruitment and monocyte trafficking, is increased by leptin, obesity, and insulin-resistance-inducing hormones [11]. Also, cellular adhesion molecules (CAMs) mediate adhesion of circulating leukocytes to endothelial cells, promoting subsequent transendothelial migration [12].

Nevertheless, few studies have evaluated adipokines, inflammatory cytokines and chemokines for their sensitivity to reflect MetS components. Therefore, we analyzed major adipose tissue-derived cytokines and chemokines, and determined the degree of association with MetS components. Abdominal computed tomography data was also generated to establish the association of blood marker with tomography measures. The identification of sensitive biomarkers is important for setting relevant targets for early nutritional and pharmacological intervention.

**Materials and Methods**

**Study subjects**

The study involved 199 subjects (108 men and 91 women). Data were collected cross-sectionally between August 2008 and March 2010. The participants were recruited from the outpatient clinic of the Department of Family Medicine at Seoul St. Mary’s Hospital, Uijeongbu St. Mary’s Hospital and St. Vincent’s Hospital in South Korea. None of the participants had been diagnosed with cardiovascular disease, infectious diseases, diseases of the liver, thyroid or kidney, malignancy, acromegaly, Cushing syndrome, or any other serious medical problems. Volunteers who were taking systemic glucocorticoids, blood glucose lowering medications (eg, metformin, thiazolidinediones), anti-inflammatory medications, and immunosuppressant drugs were also excluded. The study protocol was approved by the Institutional Review Board (IRB) of the Seoul and Uijeongbu St. Mary’s Hospital and St. Vincent’s Hospital (IRB No. KCMC08BR048). Informed consent was confirmed by the IRB. Written and informed consents were individually obtained from all the participants prior to the study.

**Anthropometric measures, blood pressure and abdominal computed tomography**

Height and weight were measured using the InBody 720 (Biospace, Seoul, South Korea). Body mass index (BMI) was calculated as body weight in kilograms divided by height in meters squared. The waist circumference was measured at the half position between the lowest rib cage and the upper iliac crest with the subject in standing position. Systolic and diastolic blood pressures were measured twice with an automatic electronic sphygmomanometer (UA-731, Takeda Medical Inc., Tokyo, Japan). The percentage of body fat was calculated by bioelectric impedance analysis using the InBody 720 (Biospace, Seoul, South Korea). Abdominal visceral and subcutaneous fat areas were measured by computed tomography scan (High Speed Advantage, General Electric Co., Evansville, IN, USA). We defined visceral obesity as a visceral fat area of more than 100 cm² [13].

**Laboratory methods**

Blood samples were drawn in the morning hours after a 12-h overnight fast. The samples were left at room temperature for 30 min, centrifuged for 15 min at 2500 rpm to separate the serum, and then stored at -70°C. Fasting serum glucose, total cholesterol, triglyceride (TG), and HDL-cholesterol
were determined using an autoanalyzer (Hitachi 747 autoanalyzer, Hitachi, Tokyo, Japan). Insulin was measured by enzyme immunoassay (Immulex 2000, Siemens, IL, USA). Serum low-density lipoprotein cholesterol concentration was calculated according to the Friedewald formula [14].

Serum adiponectin, resistin, leptin, intercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM), MCP1, TNF-α and IL-6 concentrations were measured with the enzyme-linked immunosorbent assay (ELISA) kit (Quantikine, R&D Systems, Minneapolis, MN, USA). Intraassay and interassay coefficients of variation (CVs) of analyzed adipokines, inflammatory cytokines and chemokines were as follows: adiponectin (< 4.7%, < 6.9%), resistin (< 5.3%, < 9.2%), leptin (<3.3%, 5.4%), ICAM and VCAM (< 5.2%, < 7.8%), MCP1 (< 7.8%, < 6.8%), TNF-α (< 5.2%, 7.4%), and IL-6 (< 7.8%, 9.6%).

We used the solid phase two-site enzyme immunoassay Mercodia Oxidized LDL ELISA (Mercodia, Uppsala, Sweden) to quantitatively measure oxidized low density lipoproteins (oxLDL) in serum. Serum high-sensitivity C-reactive protein (hsCRP) was measured by high-sensitively assay, using a ELISA kit (Human CRP ELISA kit, High sensitivity, Helica Biosystems Inc., Fullerton, CA, USA) with intraassay and interassay CVs less than 4.6% and 6.0%, respectively.

Criteria for MetS

The diagnosis of MetS was based on the updated National Cholesterol Education Program (NCEP) criteria [15]. Participants with three or more of the following five criteria were defined as having MetS: abdominal obesity (defined as waist circumference ≥ 90 cm for men and ≥ 85 cm for women in Korean) [16], elevated blood pressure (≥ 130 mmHg systolic and/or ≥ 85 mmHg diastolic), high fasting blood glucose (≥ 100 mg/dL), high TG (≥ 150 mg/dL), and low high-density lipoprotein (HDL) cholesterol (< 40 mg/dL for men and < 50 mg/dL for women). The third criterion, fasting blood glucose, was changed to 100 mg/dL from the initial cutoff point of 110 mg/dL according to the revised guideline [17].

Statistical analyses

The statistic analyses were performed using the SAS 9.1 program (SAS Inc., Cary, NC, USA). Differences in continuous variables of socio-demographics, body composition, and clinical and metabolic parameters and biomarkers between MetS subjects and control subjects were evaluated by the t-test for normally distributed variables and by the Wilcoxon rank-sum test for variables that were not normally distributed. Differences in categorical socio-demographics variables were evaluated by the chi-square test. The variables that did not have a normal distribution (adiponectin, resistin, leptin, ICAM, VCAM, MCP1, oxLDL, TNF-α, IL-6, hsCRP) were log-transformed before analyses. For the purpose of data presentation, these variables were again transformed to absolute values in the section “Results”. MetS score is determined by adding the number of risk factors; waist circumference, TG, HDL-cholesterol, glucose and blood pressure. The associations between MetS score and adipokines and inflammatory markers were determined by Pearson’s correlation. Multivariate logistic regression analysis was used to estimate the adjusted odds ratios (OR) and 95% confidence intervals of the adipokines and inflammatory markers, predicting MetS. In order to assess the contribution of the various adipokines and inflammation markers to the different components of the MetS, we used multiple linear regression models. The components of MetS were the dependent variables and the adipokines and inflammation markers, as well as other potential confounders, were the covariates. Confounders included age, smoking and BMI. All above analyses were considered significant at p < 0.05 (two-tailed).
Table 1. Socio-demographics, body composition, clinical, metabolic, and inflammatory parameters and adipokines in the group with and without MetS

| Variable                        | Control (n = 91) | MetS (n = 108) | p value    |
|---------------------------------|-----------------|----------------|------------|
| Socio-demographics              |                 |                |            |
| Age, yr                         | 38.0 ± 11.0     | 46.5 ± 11.5    | < 0.0001   |
| Male, %                         | 41.8            | 64.8           | 0.0011     |
| Current drinker, %              | 60.7            | 73.2           | 0.1934     |
| Current smoker, %               | 15.5            | 32.3           | 0.0014     |
| Body composition and clinical parameters |             |                |            |
| Height, cm                      | 165.1 ± 8.6     | 167.6 ± 9.0    | 0.0625     |
| Weight, kg                      | 64.9 ± 12.3     | 78.3 ± 14.2    | < 0.0001   |
| BMI, kg/m²                      | 23.7 ± 3.5      | 28.0 ± 3.4     | < 0.0001   |
| Percent body fat, %             | 27.9 ± 7.6      | 30.8 ± 5.9     | 0.0042     |
| Visceral fat area, cm²          | 97.6 ± 71.9     | 110.1 ± 56.6   | 0.0043     |
| Subcutaneous fat area, cm²      | 165.6 ± 78.1    | 147.6 ± 83.1   | 0.0268     |
| Visceral obesity, %†            | 34.1            | 49.1           | 0.0327     |
| Cholesterol, mg/dl              | 188.1 ± 30.7    | 211.7 ± 32.3   | < 0.0001   |
| LDL-cholesterol, mg/dl          | 109.9 ± 28.1    | 126.6 ± 34.8   | 0.0002     |
| Insulin, uU/ml                  | 6.8 ± 4.7       | 11.2 ± 9.5     | < 0.0001   |
| MetS factors                     |                 |                |            |
| Waist circumference, cm         | 83.5 ± 9.8      | 95.8 ± 7.6     | < 0.0001   |
| SBP, mmHg                       | 119.1 ± 12.7    | 135.5 ± 15.7   | < 0.0001   |
| DBP, mmHg                       | 71.6 ± 9.5      | 78.7 ± 13.3    | < 0.0001   |
| TG, mg/dl                       | 90.9 ± 52.9     | 212.2 ± 114.0  | < 0.0001   |
| HDL-cholesterol, mg/dl          | 60.0 ± 15.0     | 42.6 ± 12.1    | < 0.0001   |
| Glucose, mg/dl                  | 91.3 ± 6.9      | 108.5 ± 12.5   | < 0.0001   |
| Adipokine and inflammatory markers |             |                |            |
| Adiponectin, ug/ml*             | 7.1 ± 3.1       | 4.5 ± 3.0      | < 0.0001   |
| Resistin, ng/ml*                | 6.8 ± 4.0       | 8.5 ± 4.1      | 0.0017     |
| Leptin, ng/ml*                  | 5.9 ± 6.9       | 7.4 ± 5.8      | 0.0005     |
| VCAM, ng/ml*                    | 439.7 ± 68.5    | 427.5 ± 75.3   | 0.1468     |
| ICAM, ng/ml*                    | 118.6 ± 49.1    | 167.0 ± 65.4   | < 0.0001   |
| MCP1, pg/ml*                    | 246.7 ± 80.7    | 305.0 ± 92.6   | < 0.0001   |
| oxLDL, U/L*                     | 66.2 ± 17.3     | 85.0 ± 22.3    | < 0.0001   |
| TNF-α, pg/ml*                   | 3.4 ± 3.9       | 6.7 ± 5.8      | < 0.0001   |
| IL-6, pg/ml*                    | 2.8 ± 2.0       | 3.4 ± 1.5      | 0.0002     |
| hsCRP, mg/dL*                   | 0.1 ± 0.1       | 0.3 ± 0.5      | < 0.0001   |

Values are presented as mean ± SD or (%).
SBP: systolic blood pressure, DBP: diastolic blood pressure, TG: triglyceride, VCAM: vascular cell adhesion molecule, ICAM: intercellular adhesion molecule, MCP1: monocyte chemoattractant protein 1, oxLDL: oxidized low-density lipoprotein, TNF-α: tumor necrosis factor-alpha, IL-6: interleukin-6, hsCRP: High-sensitivity C-reactive Protein.
*These variables were log-transformed before analysis; †Visceral obesity was defined as a visceral fat area (VFA) measuring > 100 cm² by CT scanning [13].

Significantly higher serum levels of resistin (p < 0.01), leptin (p < 0.001), ICAM (p < 0.0001), MCP1 (p < 0.0001), oxLDL (p < 0.0001), TNF-α (p < 0.0001), IL-6 (p < 0.001) and hsCRP (p < 0.0001) than subjects without MetS. By contrast, serum adi-
Adiposity-Related Biomarkers and MetS

Adiponectin levels were significantly lower in subjects with MetS (p < 0.0001). There was no difference in serum VCAM concentration. Also, the MetS group had a larger proportion of subjects who were visceral obesity compared to control group (p < 0.05).

The Pearson’s partial coefficients of correlation between the MetS score and blood markers are shown in Table 2. The correlation analysis indicated that the MetS score had an inverse relationship with adiponectin (r = -0.325, p < 0.0001), and positive correlations with leptin (r = 0.197, p < 0.05), ICAM (r = 0.244, p < 0.01), MCP1 (r = 0.180, p < 0.05), oxLDL (r = 0.188, p < 0.05), TNF-α (r = 0.316, p < 0.0001), IL-6 (r = 0.170, p < 0.05) and hsCRP (r = 0.242, p < 0.01).

The odds ratios of having MetS as a function of each adipokine and inflammation marker after adjusting for age, sex, BMI and smoking are shown in Table 3. MetS was significantly associated with increments in TNF-α (OR = 4.78, p < 0.01), IL-6 (OR = 7.60, p < 0.0001), and hsCRP (OR = 2.72, p < 0.05). The odds ratio of MetS with high adiponectin was 0.42 (p < 0.05).

The multiple linear relationships of each metabolic component to adipokine and inflammatory parameters are shown in Table 4. Waist was independently and significantly associated with MCP1 and the standardized β coefficient was 0.117. TNF-α was independently associated with glucose with a standardized β value of 0.228. TG was independently associated with adiponectin, ICAM and TNF-α; the standardized β coefficients were -0.213, 0.197, and 0.193, respectively. Also, HDL-cholesterol was independently associated with adiponectin, ICAM and hsCRP with standardized β coefficients of 0.214, -0.150, and -0.173, respectively.

The relationship between the visceral and subcutaneous fat area measured by computed tomography scan and adipokines and inflammation markers after adjusting for age, sex, smoking, and BMI are shown in Table 5. The correlation analysis showed a positive relationship between visceral fat area and leptin (r = 0.184, p < 0.05) and hsCRP (r = 0.156, p < 0.05). The subcutaneous fat area positively correlated with leptin (r = 0.305, p < 0.0001) and hsCRP (r = 0.228, p < 0.01), while it negatively correlated with TNF-α (r = -0.157, p < 0.05).

Discussion

A cluster of risk factors including obesity, insulin resistance, hypertension and dysregulated lipoproteins have been included as features of MetS. However, there are ongoing debates regarding appropriate application of these components as diagnostic tools for MetS in clinical practices. In this study, we identified the relationship between the components of MetS and inflammation-related biomarkers to determine possible application for these biomarkers in the diagnosis of MetS. Despite current use of MetS components, studies have indicated that inflammatory markers need to be incorporated to fully

Table 2. Relationship between MetS score and adipokine and inflammatory parameters

| Variable | MetS score | p value | MetS score adjusted age, sex, smoking, and BMI | p value |
|----------|------------|---------|-----------------------------------------------|---------|
| Adiponectin* | -0.431 | <0.0001 | -0.325 | <0.0001 |
| Resistin* | 0.290 | <0.0001 | 0.091 | 0.2594 |
| Leptin* | 0.324 | <0.0001 | 0.197 | 0.0145 |
| VCAM* | -0.043 | 0.5475 | -0.040 | 0.6214 |
| ICAM* | 0.400 | <0.0001 | 0.244 | 0.0023 |
| MCP1* | 0.335 | <0.0001 | 0.180 | 0.0254 |
| oxLDL* | 0.468 | <0.0001 | 0.188 | 0.0197 |
| TNF-α* | 0.318 | <0.0001 | 0.316 | <0.0001 |
| IL-6* | 0.248 | 0.0004 | 0.170 | 0.0354 |
| hsCRP* | 0.484 | <0.0001 | 0.242 | 0.0025 |

Data are given as Pearson’s correlation (R) coefficients.

VCAM: vascular cell adhesion molecule, ICAM: intercellular adhesion molecule, MCP1: monocyte chemoattractant protein 1, oxLDL: oxidized low-density lipoprotein, TNF-α: tumor necrosis factor-alpha, IL-6: interleukin-6, hsCRP: High-sensitivity C-reactive Protein.

*These variables were log-transformed before analysis.
understand the risk of clinical complications [18,19].

Study results indicated that body composition measures and inflammation-related biomarkers were significantly different between subjects with and without MetS. Obesity-related indicators such as waist circumference and BMI have been used to predict of MetS [20]. More recently, visceral fat as a metabolically active tissue has been suggested to have a close relationship with MetS. It is associated with higher production of inflammation mediators including TNF-α [21], plasminogen activator inhibitor-1 (PAI-1) [22], IL-6, and hsCRP [20]. In the present study, subjects with MetS showed a higher visceral fat area compared to control subjects. However, subjects with MetS had less subcutaneous fat area compared to the control subjects.

The MetS score had a positive relationship to the circulating concentrations of adipokine and most pro-inflammatory markers except resistin and VCAM. Previous studies have also suggested that the presence of MetS was associated with higher levels of IL-6, TNF-α, and hsCRP and with lower levels of adiponectin [20]. MetS score is determined by adding the number of risk factors; waist circumference, TG, HDL-cholesterol, glucose and blood pressure. A patient is classified as having MetS when the MetS score is more than 3. The higher their MetS score indicates the higher their risk of having or developing metabolic diseases. Our study results indicated that most of

Table 3. Odds ratio† for MetS according to adipokine and inflammatory markers

| (N = 199)  | OR (95% CI) | p value |
|-----------|------------|---------|
| Adiponectin* | 0.42 (0.18-0.94) | 0.0355 |
| Resistin* | 1.60 (0.71-3.63) | 0.2614 |
| Leptin* | 1.49 (0.63-3.52) | 0.3592 |
| VCAM* | 0.50 (0.22-1.10) | 0.0860 |
| ICAM* | 1.58 (0.69-3.62) | 0.2796 |
| MCP1* | 1.62 (0.72-3.64) | 0.2439 |
| oxLDL* | 1.82 (0.76-4.40) | 0.1843 |
| TNF-α* | 4.78 (1.90-12.28) | 0.0090 |
| IL-6* | 7.60 (2.99-19.31) | <0.0001 |
| hsCRP* | 2.72 (1.15-6.42) | 0.0228 |

OR (odds ratios) were adjusted for age, sex, BMI, and smoking. Cl: confidence interval, VCAM: vascular cell adhesion molecule, ICAM: intercellular adhesion molecule, MCP1: monocyte chemoattractant protein 1, oxLDL: oxidized low-density lipoprotein, TNF-α: tumor necrosis factor-alpha, IL-6: interleukin-6, hsCRP: High-sensitivity C-reactive Protein. *These variables were log-transformed before analysis; †75th percentile cut-off.

Table 4. Multiple linear regression analysis with the adipokine and inflammatory parameters as independent variables and the components of MetS as dependent variables

| Component of MetS | Adipokine and inflammatory parameters |
|-------------------|--------------------------------------|
|                   | Adiponectin | Resistin | Leptin | VCAM | ICAM | MCP1 | oxLDL | TNF-α | IL-6 | hsCRP |
| Waist circumference | -0.034 | 0.087 | -0.050 | 0.030 | 0.051 | 0.117 | 0.106 | 0.039 | -0.038 | 0.028 |
| SBP | -0.032 | 0.011 | -0.087 | 0.057 | 0.018 | 0.124 | 0.064 | 0.102 | -0.036 | -0.013 |
| DBP | -0.015 | 0.023 | -0.083 | -0.085 | 0.040 | 0.015 | -0.017 | 0.006 | -0.041 | 0.023 |
| TG | -0.213 | -0.047 | -0.100 | -0.046 | 0.197 | -0.019 | -0.022 | 0.193 | -0.049 | 0.095 |
| HDL-cholesterol | 0.024 | 0.577 | 0.236 | 0.532 | 0.018 | 0.815 | 0.816 | 0.0138 | 0.5368 | 0.2618 |
| Glucose | 0.214 | 0.008 | -0.062 | -0.012 | -0.150 | -0.035 | -0.116 | -0.079 | -0.026 | -0.073 |
| SBP: systolic blood pressure, DBP: diastolic blood pressure, TG: triglyceride, VCAM: vascular cell adhesion molecule, ICAM: intercellular adhesion molecule, MCP1: monocyte chemoattractant protein 1, oxLDL: oxidized low-density lipoprotein, TNF-α: tumor necrosis factor-alpha, IL-6: interleukin-6, hsCRP: High-sensitivity C-reactive Protein. *These variables were log-transformed before analysis; †Standardized Coefficients.
Adiposity-Related Biomarkers and MetS

the inflammation markers and adipokines showed a significant relevance with the MetS score. After adjusting possible confounders including age, sex, BMI and smoking, adiponectin was shown to have a strong negative relationship with the MetS score, and the OR of MetS was 0.42. Plasma adiponectin is often found to be positively correlated with HDL-cholesterol and insulin sensitivity, whereas inverse correlations with central adiposity, TG levels, and hsCRP concentrations have been observed [23,24]. Devaraj and colleagues [25] reported that low adiponectin was the strongest predictor of MetS (OR, 2.5; 95% CI, 1.3-4.5). Adiponectin is the most abundant adipokine in circulation and it exerts anti-inflammatory activity. It has been demonstrated that adiponectin modulates insulin sensitivity by stimulating glucose utilization and fatty acid oxidation via phosphorylation and activation of AMPK in muscle and liver [26]. Adiponectin also possesses vasculo-protective effects which are mediated by promoting vasodilatation and vascular repair, and inhibiting ROS formation, macrophage activation and smooth muscle cell proliferation [27].

Among others, ICAM, hsCRP and TNF-α concentrations exhibited strong correlations with the MetS score. The initial stages of atherosclerosis are characterized by adhesion of circulating leukocytes to the endothelial cells and subsequent transendothelial migration. This process is mediated in part by CAMs like ICAM-1 which are expressed on the endothelial membrane [12]. In a recent cohort study, baseline ICAM-1 was increased initially in healthy middle-aged men who later developed cardiovascular disease [28] indicating this adhesion molecule is an important predictor for cardiovascular complications.

hsCRP is a marker of systemic inflammation which has been known to be related to cardiovascular disease risk factors such as obesity, high blood pressure, apolipoprotein B and fibrinogen [29]. hsCRP is also known to impair insulin signaling. In previous studies, strong associations between hsCRP and insulin resistance have been reported [30].

TNF-α is a most representative pro-inflammatory cytokine which is produced mainly by macrophages and lymphocytes. Prior studies have demonstrated that the infiltration of macrophages in adipose tissue increases TNF-α expression followed by adhesion molecule induction [31]. TNF-α also inhibits the insulin signaling cascade at several pivotal regulatory proteins, such as the insulin receptor substrate (IRS) and Akt substrate 160 in human skeletal muscle in vivo [32]. In human studies, insulin sensitivity correlated with plasma soluble TNF receptor 2 (TNFR-2) after adjustment for multiple confounders in the healthy adults [33]. IL-6 is another pro-inflammatory cytokine related to insulin resistance. IL-6 has also been shown to facilitate the hepatic production of hsCRP [34]. Leptin is known as a TNF-α inducer while adiponectin is a suppressor.

Table 5. Relationship between the visceral and subcutaneous fat area and the adipokine and inflammatory biomarkers adjusting for age, sex, smoking, and BMI

|                      | Visceral fat area | Subcutaneous fat area |
|----------------------|------------------|-----------------------|
|                      | Coefficients     | p value               | Coefficients     | p value               |
| Adiponectin*         | 0.024            | 0.7594                | 0.062            | 0.4207                |
| Resistin*            | 0.011            | 0.8853                | -0.057           | 0.4591                |
| Leptin*              | 0.184            | 0.0158                | 0.305            | <0.0001               |
| VCAM*                | 0.075            | 0.3296                | 0.054            | 0.4802                |
| ICAM*                | 0.085            | 0.2691                | 0.027            | 0.7205                |
| MCP1*                | 0.039            | 0.6114                | 0.118            | 0.1239                |
| oxLDL*               | 0.090            | 0.2378                | 0.051            | 0.5081                |
| TNF-α*               | -0.048           | 0.5328                | -0.157           | 0.0393                |
| IL-6*                | -0.038           | 0.6246                | 0.013            | 0.8652                |
| hsCRP*               | 0.156            | 0.0404                | 0.228            | 0.0027                |

Data are given as Pearson’s correlation (R) coefficients.
VCAM: vascular cell adhesion molecule, ICAM: intercellular adhesion molecule, MCP1: monocyte chemoattractant protein 1, oxLDL: oxidized low-density lipoprotein, TNF-α: tumor necrosis factor-alpha, IL-6: interleukin-6, hsCRP: High-sensitivity C-reactive Protein.
*These variables were log-transformed before analysis.
These results suggest that adipokines including leptin and adiponectin mediate the production of inflammatory cytokines and CAMs possibly leading the development of insulin resistance and vascular complications. Our study results confirmed that MetS score and inflammatory markers are closely related. The odds ratio value indicated that adiponectin, TNF-α, IL-6 and hsCRP are strongly related to MetS highlighting the fact that these may be important mediators for metabolic disease development and should be targets for future intervention.

Few studies have analyzed the relative weight of each MetS components in predicting inflammatory responses. Results from this study indicated that both TG and HDL-C were closely related to the concentration of inflammatory markers next to the MetS score (Table 4). Lipid metabolism and cytokine production seem to have a cross-talk pathophysiological response. During the acute-phase response to inflammation, cytokines induce tissue and plasma events that lead to changes in lipoprotein. TNF-α acutely raises serum TG levels in vivo by stimulating very low-density lipoprotein (VLDL) production [35]. In healthy people, a positive association between the plasma concentration of the soluble fraction of TNFR-2 and total TG has been reported, which paralleled a negative one with HDL-cholesterol [36]. Therefore, the acute-phase response induced by cytokines, such as TNF-α and hsCRP, may include a characteristic dyslipidemia (raised TG and lowered HDL-cholesterol) and other process promoting atherosclerosis.

We also measured abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) by CT to determine the relationship between fat tissue mass and biomarkers. Adipose tissue pathogenicity differs according to adipose tissue localization [37]. VAT was suggested as an independent predictor of impaired glucose tolerance, elevated blood pressure, and dyslipidemia [38,39]. It is more susceptible to lipolysis than SAT [21], and is associated with a higher production of hsCRP [20]. Pou and colleagues [40] examined the relationship of abdominal SAT and VAT volume to circulating inflammatory and oxidative stress biomarkers and concluded that SAT and VAT were similarly associated with elevated concentrations of multiple inflammatory biomarkers [40]. Our study results indicated that both VAT and SAT were significantly related to leptin and hsCRP. This finding indicated that both VAT and SAT contributed to the elevated production of inflammation-related molecules.

Although this study provided information on sensitivity of inflammation-related biomarkers associated with Met score, there are limitations. Due to the cross-sectional design of this study, it was not possible to establish a cause–effect relationship between adipokines and inflammatory biomarkers and MetS. Therefore, prospective or longitudinal studies are necessary to further elucidate the association between serum adipokines, inflammatory biomarkers and MetS. Also, we did not consider behavioral factors and dietary factors which may play important roles in the link between MetS and adipokines and inflammatory biomarkers.

In summary, the circulating adiponectin, TNF-α, IL-6 and hsCRP were the most proximate mediators linking obesity, MetS and metabolic diseases in this study. Blood TG and HDL-cholesterol concentrations displayed close relationships with various inflammatory markers studied suggesting disturbances in lipid metabolism may be major events related to MetS prior to the development of metabolic diseases.

Acknowledgments

This work was supported by the Ministry of Knowledge Economy, Republic of Korea for the Regional Innovation System program in 2007 (No. B0009639), and National Research Foundation of Korea (NRF) grant (grant number 2008-0062618 and 2012R1A2A2A01046228) funded by the Korea government (MSIP: Ministry of Science, ICT & Future Planning).

References

1. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-36.
2. Türkoglu C, Duman BS, Güraydın D, Cağatay P, Özcan R, Büyükküçük AS. Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature. Obes Surg 2003;13:699-705.
3. Calabro P, Yeh ET. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep 2008;10:32-8.
4. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
5. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, Vestergaard H. Low-grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol 2010;143:35-42.
6. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immuno- nol 2005;174:3137-42.
7. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004;323:630-5.
8. Zhao T, Hou M, Xia M, Wang Q, Zhu H, Xiao Y, Tang Z, Ma J, Ling W. Globular adiponectin decreases leptin-induced tumor necrosis factor-alpha expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol 2005;238:19-30.
9. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new feature. Obes Surg 2003;13:699-705.
Adiposity-Related Biomarkers and MetS

20. You T, Nicklas BJ, Poole S, Jose PJ, Cortijo J, Morcillo EJ, Sanz MJ. A critical role for TNFalpha in the selective activation of mononuclear leukocytes to angiotensin-II-stimulated arterioles. Blood 2007;110:1895-902.

11. Kralsch S, Bluhm M, Paschke R, Stummvoll M, Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem 2007;7:39-45.

12. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.

13. Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J 2002;66:987-92.

14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

16. Lee S, Park HS, Kim SM, Kwon HS, Kim DY, Kim DJ, Cho GJ, Han JH, Kim SR, Park CY, Oh SJ, Lee CB, Kim KS, Oh SW, Kim YS, Choi WH, Yoo HJ. Cut-off points of waist circumference for defining abdominal obesity in the Korean population. Korean J Obes 2006;15:1-9.

17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.

18. Aguilante CL, Kosiński LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism 2008;57:494-501.

19. Jung CH, Lee WY, Kim SY, Shin HS, Kim HD, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW. The risk of metabolic syndrome according to the waist circumference of apparently healthy Koreans. Int J Cardiol 2008;129:266-71.

20. You T, Nicklas BJ, Ding J, Penninx BW, Goodpaster BH, Bauer DC, Ty 10. Mateo T, Naim Abu Nabah Y, Losada M, Estellés R, Company C, Bedrina 16. Lee S, Park HS, Kim SM, Kwon HS, Kim DY, Kim DJ, Cho GJ, Han JH, Kim SR, Park CY, Oh SJ, Lee CB, Kim KS, Oh SW, Kim YS, Choi WH, Yoo HJ. Cut-off points of waist circumference for defining abdominal obesity in the Korean population. Korean J Obes 2006;15:1-9.

21. van Harmelen V, Dicker A, Rydén M, Hauner H, Lönnqvist F, Näslund I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:1441-7.

22. Marcos M, Namioka K, Katacayso S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol 2008;159:677-80.

23. Matsubara M, Namioka K, Katacayso S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol 2003;148:657-62.

24. Matsubara M, Namioka K, Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol 2003;148:657-62.